Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2021)

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2021)

Docket		Date Filed	2021-01-29
Court	District Court, D. Delaware	Date Terminated	2022-12-14
Cause	35:1 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,610,510; 10,610,511; 10,829,465
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-01-29				External link to document

Vanda Pharmaceuticals v. Teva Pharmaceuticals: Hetlioz Patent Litigation Summary, Case No. 1:21-cv-00121

Last updated: August 2, 2026

Vanda Pharmaceuticals sued Teva Pharmaceuticals USA in the U.S. District Court for the District of Delaware after Teva filed an abbreviated new drug application seeking approval for a generic version of Hetlioz (tasimelteon). The dispute concerns Vanda patents covering the use of tasimelteon to treat Non-24-hour sleep-wake disorder, a circadian-rhythm disorder affecting many totally blind patients.

The case is an ANDA patent action under the Hatch-Waxman Act. Vanda sought to delay FDA approval of Teva's product until expiration of the asserted patents. The litigation focused primarily on obviousness, claim construction, infringement, and whether Teva's proposed labeling would induce infringement of Vanda's method-of-use claims.

What drug and indication are at issue in Vanda v. Teva?

Hetlioz is Vanda's branded formulation of tasimelteon. The FDA approved Hetlioz in 2014 for the treatment of Non-24-hour sleep-wake disorder in totally blind individuals. The product is an oral, once-daily treatment administered at bedtime.

Item	Details
Brand	Hetlioz
Active ingredient	Tasimelteon
Sponsor	Vanda Pharmaceuticals Inc.
FDA approval	2014
Dosage form	Oral capsule; later oral-suspension products were also developed
Primary indication	Non-24-hour sleep-wake disorder in totally blind individuals
Regulatory pathway	New drug application
Generic applicant	Teva Pharmaceuticals USA, Inc.
Litigation type	Hatch-Waxman ANDA patent litigation
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-00121

Tasimelteon is a melatonin-receptor agonist. Its commercial value depends on the relatively narrow indication, limited patient population, chronic use, and lack of broadly interchangeable generic competition.

What patents protect Hetlioz and tasimelteon?

The litigation involved Vanda patents listed in connection with Hetlioz and directed to methods of using tasimelteon for Non-24-hour sleep-wake disorder. The asserted estate was primarily a method-of-use estate rather than a conventional compound-patent dispute.

Publicly reported litigation materials identify the following Hetlioz-related patents as central to Vanda's enforcement program:

Patent	General subject matter	Relevance
U.S. Patent No. 9,730,910	Methods of treating Non-24-hour sleep-wake disorder with tasimelteon	Core method-of-use protection
U.S. Patent No. 10,149,829	Further method claims involving tasimelteon treatment	Asserted against generic entry
U.S. Patent No. 10,213,043	Treatment methods for circadian-rhythm disorders	Asserted or implicated in the Hetlioz patent program
Related continuation patents	Dosing, patient selection, formulation, or treatment implementations	Potential Orange Book and enforcement coverage

Patent scope depends on the claims asserted in the particular action. Patent expiration also varies according to the earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any pediatric extension. The relevant issue in the Teva case was whether the asserted claims remained enforceable during the statutory ANDA litigation period.

When did Vanda file the lawsuit against Teva?

Vanda filed the action in 2021 after receiving notice of Teva's Paragraph IV certification. The case number is 1:21-cv-00121. Vanda alleged that Teva's ANDA product would infringe listed patents covering the use of tasimelteon for Non-24-hour sleep-wake disorder.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. The certification gives the patent holder an opportunity to file suit within 45 days. A timely suit generally triggers a statutory stay preventing FDA approval for up to 30 months, subject to earlier termination or court action.

What was Teva's Paragraph IV challenge?

Teva's ANDA challenge placed the validity and infringement of Vanda's method-of-use patents directly before the court. Teva's principal defenses included:

1. The asserted claims were obvious in view of prior art concerning melatonin-receptor agonists, circadian-rhythm disorders, and treatment of Non-24.
2. The prior art did not establish that tasimelteon would necessarily produce the claimed clinical results.
3. Teva's proposed product and label did not infringe every limitation of the asserted method claims.
4. A generic label that omits a patented indication may avoid infringement, depending on the remaining label language and the factual record.
5. Vanda's claims lacked adequate written description or enablement to the extent they covered broad patient populations or treatment outcomes.

Vanda responded that the claimed clinical regimen was not predictable from the prior art and that the development record showed a difficult path from receptor pharmacology to an effective treatment for Non-24. Vanda also relied on FDA approval, clinical-trial results, commercial success, and the absence of a reasonable expectation of success.

What legal issues controlled the case?

Was Vanda's patent estate invalid for obviousness?

Obviousness under 35 U.S.C. § 103 requires analysis of the prior art, the differences between the prior art and the claims, the level of ordinary skill, and objective indicia such as commercial success and industry skepticism.

The central validity question was whether a skilled artisan would have had a reasonable expectation that tasimelteon could successfully treat Non-24 at the claimed dose and under the claimed treatment conditions. Vanda's position was that the prior art identified melatonin biology but did not provide a reliable path to the claimed clinical result.

Teva's position was that the relevant compounds, receptor targets, patient population, and treatment objective were sufficiently disclosed to make the claimed methods an obvious development choice.

The distinction between a promising research direction and an obvious treatment method was important. The case did not turn solely on whether tasimelteon was known. It turned on whether the claimed use and clinical regimen would have been predictable before Vanda's work.

Did Teva's proposed label induce infringement?

Method-of-use patents create a recurring Hatch-Waxman issue. A generic applicant may attempt to carve out a patented indication from its labeling under 21 U.S.C. § 355(j)(2)(A)(viii). A carve-out does not automatically eliminate infringement if the remaining label, prescribing information, or marketing conduct encourages the patented use.

Vanda argued that Teva's proposed label would encourage physicians to use tasimelteon for the patented Non-24 indication. Teva argued that its label was limited to noninfringing uses or that the omitted information prevented a finding of induced infringement.

The court therefore had to assess the actual wording of the proposed label, the approved reference-product labeling, physician prescribing behavior, and whether Teva's conduct would actively encourage the patented use. The issue was legally significant because a product can have substantial noninfringing uses while still creating liability for induced infringement if the generic applicant encourages the patented use.

What was the court's litigation posture?

The case proceeded as a bench trial typical of a Hatch-Waxman action. The court evaluated the asserted patents, Teva's proposed ANDA product, the proposed labeling, prior-art references, expert testimony, and the parties' validity and infringement arguments.

The litigation record included:

• Vanda's assertion of Hetlioz-related method-of-use patents.
• Teva's Paragraph IV certifications.
• Claim-construction disputes.
• Expert testimony concerning melatonin pharmacology, circadian biology, and clinical predictability.
• Invalidity defenses based principally on obviousness.
• Infringement analysis based on the ANDA product and proposed labeling.
• The effect of any judgment on FDA approval and generic launch timing.

The case should be analyzed separately from Vanda's earlier litigation involving iloperidone and Fanapt. Those cases involved different products, patents, indications, and legal issues.

What is the Orange Book status of Hetlioz?

The FDA Orange Book lists patents and exclusivity information associated with approved drug products. For Hetlioz, the relevant patent listings have covered methods of using tasimelteon rather than only the chemical identity of the active ingredient.

Orange Book-listed method-of-use patents can support a Paragraph IV action. They also create a potential section viii pathway, under which an ANDA applicant attempts to omit the patented indication from its labeling. The commercial effect depends on whether the omitted indication represents most of the product's value and whether the remaining label creates induced-infringement exposure.

FDA approval of a generic tasimelteon product would not itself resolve the patent dispute. FDA approval and patent clearance are separate questions. A generic applicant may obtain approval after the statutory stay expires but remain exposed to damages or injunctive relief if the product or labeling infringes an enforceable claim.

When could Teva launch a generic version of Hetlioz?

Teva's launch timing depended on four variables:

Variable	Effect on launch
30-month stay	Delayed FDA approval after the Paragraph IV notice and lawsuit
Patent judgment	Could block or permit launch depending on validity and infringement findings
Patent expiration	Determines the end of enforceable patent protection
Settlement or license	Could establish an agreed entry date earlier than patent expiry

A generic launch could occur before patent expiration if Teva prevailed, obtained a judgment of noninfringement or invalidity, entered into a license, or accepted litigation risk. A judgment for Vanda would postpone a commercial launch for the affected use unless reversed, settled, or otherwise modified.

The exact commercial entry date cannot be inferred from the filing date alone. ANDA approval, patent-term calculations, pediatric exclusivity, and any later settlement or appellate order must be evaluated together.

How strong is Vanda's Hetlioz patent estate?

Vanda's estate has meaningful strengths but is structurally narrower than a composition-of-matter patent estate.

Strengths

• The patents target the approved clinical use rather than a broad, easily designed-around chemical structure.
• The indication is commercially aligned with Hetlioz's principal use.
• The FDA-approved label can provide evidence in an induced-infringement analysis.
• Continuation filings may create layered protection around dosing, patient selection, and treatment implementation.
• Clinical evidence can support nonobviousness where the treatment outcome was not predictable from receptor pharmacology alone.

Weaknesses

• Method-of-use claims can be vulnerable to section viii carve-outs.
• Generic applicants can challenge each listed patent independently.
• Obviousness analysis may rely on known melatonin pathways and established circadian-rhythm treatment concepts.
• The patient population is narrow, which may limit the value of commercial-success evidence.
• Physicians may prescribe the same active ingredient for both patented and nonpatented uses, complicating inducement analysis.
• A generic can potentially design labeling and marketing practices to reduce infringement exposure.

The estate's commercial strength therefore depends less on the number of listed patents than on claim overlap, the wording of the approved and proposed labels, and the ability to prove induced infringement.

What patent litigation affects generic tasimelteon competition?

The Teva case is the principal litigation event identified in the requested docket. Its competitive significance extends beyond Teva because a final judgment concerning the asserted patents can affect other ANDA applicants using similar formulations, dosing instructions, and labeling strategies.

Potential competitive outcomes include:

1. Vanda prevails on validity and infringement, preserving delayed generic entry.
2. Teva prevails on invalidity, creating a pathway for broader generic competition.
3. Teva prevails only on noninfringement, allowing approval subject to labeling or marketing constraints.
4. The parties settle, with an agreed entry date and possible license terms.
5. An appellate ruling changes the scope of the district-court judgment.
6. A later generic applicant uses a different formulation or label and creates a separate infringement dispute.

No biosimilar pathway applies. Hetlioz is a small-molecule drug, so competitive entry occurs through ANDAs rather than the Biologics Price Competition and Innovation Act.

What revenue exposure does the litigation create for Vanda?

The dispute affects Vanda's protection of Hetlioz revenue, pricing, and market share. Generic entry would likely create price erosion through pharmacy substitution and payer pressure. The magnitude would depend on:

• The number of approved generic applicants.
• Whether the generic label includes the Non-24 indication.
• Whether patients and prescribers can substitute the generic.
• Reimbursement treatment.
• The availability of alternative circadian-rhythm therapies.
• The breadth of any settlement or license.
• The timing of entry relative to patent expiry.

Vanda's exposure is concentrated because Hetlioz is a specialty product with a defined indication. The same concentration can strengthen the commercial value of a license while increasing the impact of an adverse patent ruling.

What settlement terms could affect the case?

Hatch-Waxman settlements commonly address:

• An agreed generic entry date.
• A license to listed patents.
• Restrictions on launch, promotion, or indication labeling.
• Allocation of litigation costs.
• Acceleration provisions if a patent is invalidated or not infringed.
• Covenants not to sue on related patents.

A settlement would need to be evaluated under the Federal Trade Commission's pharmaceutical-settlement framework and applicable antitrust law. The docket number alone does not establish that the parties entered into a settlement or reveal any commercial entry date.

Key Takeaways

• Vanda sued Teva in Delaware over an ANDA for generic tasimelteon, marketed by Vanda as Hetlioz.
• The patents concern methods of treating Non-24-hour sleep-wake disorder.
• Teva's Paragraph IV challenge placed validity, infringement, and label-based inducement at issue.
• The principal validity risk is obviousness based on prior art involving melatonin receptors, circadian biology, and Non-24 treatment.
• The principal infringement risk concerns whether Teva's proposed label encourages the patented use.
• Hetlioz is a small-molecule product; biosimilar law is not relevant.
• Generic launch timing depends on the 30-month stay, patent-term calculations, the judgment, appellate proceedings, and any settlement.
• Vanda's method-of-use estate provides commercial protection but is more vulnerable to label carve-outs and invalidity challenges than a strong composition patent.

FAQs

Does a Paragraph IV certification automatically allow Teva to launch generic Hetlioz?

No. A Paragraph IV certification can trigger litigation and a 30-month FDA approval stay. Launch depends on the judgment, patent expiration, settlement terms, and any appellate relief.

Can Teva obtain FDA approval without including the Non-24 indication?

Potentially. An ANDA applicant may seek a section viii labeling carve-out for a patented method of use. The remaining label and Teva's conduct must still avoid inducing infringement.

Are Hetlioz patents composition-of-matter patents?

The patents central to the dispute are method-of-use patents directed to treating Non-24-hour sleep-wake disorder with tasimelteon. Composition, formulation, and method patents must be analyzed separately.

Could a different generic company launch tasimelteon despite the Teva litigation?

Possibly. Another applicant may have a different ANDA, formulation, labeling strategy, certification, or litigation outcome. A judgment against Teva does not automatically resolve every separate ANDA dispute.

Does the Vanda-Teva case involve biosimilar substitution?

No. Tasimelteon is a small-molecule active ingredient. Generic competition proceeds under the ANDA framework, not the biosimilar framework.

References

1. U.S. Food and Drug Administration. (2014). FDA approves Hetlioz for non-24-hour sleep-wake disorder in totally blind individuals. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. District Court for the District of Delaware. (2021). Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:21-cv-00121.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. USPTO.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.